NuvOx Therapeutics Inc – Mobilizing Oxygen, Transforming Lives

Nuvoxpharma.com | Rong Wang| rwang@nuvoxpharma.com |520-624-6688

COMPANY OVERVIEW

A Phase IIb platform biotech company, NuvOx develops a drug that improves the flow of oxygen from lungs to blood and from blood to tissue. Our first-in-class oxygen therapeutic will treat life-threatening diseases where hypoxia plays a role (hypoxia weakens effectiveness for cancer treatments and causes brain death in stroke). Our product is the first material to reverse tissue hypoxia. Carrying ~1,000 x as much O_2 as liquids, it is injected IV and is fully synergistic with standard of care (SOC). We have positive Phase Ib/IIa human data in glioblastoma (GBM) and stroke, pre-clinical data in immuno-oncology and acute respiratory distress syndrome (ARDS). Our product is de-risked: Similar technology was commercialized as #1 selling contrast agent worldwide. We have safety data from > 2,000 subjects, strong patent protection, non-dilutive funding, and full-fledged organization and facility infrastructure.

MARKET & COMMERCIALIZATION STRATEGY

- GBM $300M+ worldwide revenue, entry point to 17bn+ oncology Serviceable Available Market (SAM)
- Stroke $4bn+ worldwide revenue
- ARDS: $1-2bn worldwide revenue

Our first customers are comprehensive centers for cancer, stroke, and respiratory care. We intend to leverage our trial sites and KOL for initial launch, after which we partner with large pharma companies or develop our own global commercial team.

TECHNICAL & COMPETITIVE ADVANTAGE

A gas-based active pharmaceutical ingredient (API) emulsified into liquid with a unique surfactant, the formulation creates a much safer and more effective method to deliver oxygen (200-1000x safer and more effective than similar material, and 1000x more effective than liquid). Compared to other clinical stage companies to address oncology and stroke as radiosensitizer and neuroprotectant, we are more advanced in clinical development, have broader market coverage, and fit with SOC perfectly. For ARDS, using our product can avoid invasive ventilators and the associated injury/mortality.

REGULATORY STRATEGY & INTELLECTUAL PROPERTY

- 8 patent families, 9 issued US patents and foreign equivalent; New IP to file for new critical excipient
- Potentially regulated as biologics: 12 years market exclusivity; Orphan drug GBM & Sickle cell: Fast Track pathway
- 10 employees and experienced consultants; In-house manufacturing, ISO7/ISO5 clean room; Established QMS

KEY MILESTONES

- Q2 2023: Commenced Phase IIb GBM trial
- Q3 2023: Closed oversubscribed convertible note: $7M
- 2024: Commence Phase IIb stroke and Phase Ib ARDS trial, raise next round

CAPITALIZATION HISTORY

YEAR	FUNDING TYPE	DESCRIPTION	AMOUNT
To date	Non-dilutive	NIH, DoD, and NIHR Grants	$15M Equiv. (~$6M active)
2019 & Prior	Series A	Individual investors (Raised)	$10.4M
2021- 2023	Bridge	Angels (40% oversubscribed)	$7M
2024 and beyond	Series B	Institutions (To Commence 2024)	$15-25M

USE OF PROCEEDS

Completion of Phase IIb GBM trial and bring GBM to market; Start pivotal stroke trial and advance other assets.

MANAGEMENT TEAM

- **CEO/Co-Founder—Dr. Evan Unger:** 4 biotech/3 FDA approved drugs**;** Multiple successful exits (>20x ROI)
- **COO/CFO—Rong Wang, CFA:** 20+ years in public and VC life sciences space; Multiple successful exits
- **CSO/Co-Founder—Dr. Jenny Johnson:** Award winning scientist/regulatory/quality, Roche
- **SVP Strategy—Dr. Nina Ossana:** IP examiner and Tech Transfer – Johns Hopkins Medical School
- **Board:** Include former Roche Executive and 17th Surgeon General of the United States
- **SAB:** CMC/Supply Chain expert, world-renowned neuro-oncologist, and stroke KOL/advisors